OK, I may take some heat for this, but I have always been puzzled as to why MNTA/Wheeler decided to pursue M118 in the first place without a designated partner from the beginning. While it may fulfill a role in ACS, the numbers needed for a trial and the sheer cost of the trial should have been realized at the beginning. Rather than spend their time and dollars on development and earlier studies on M-118, the dollars could have been targeted to a designed drug that that would not have such expensive clinical trials.
Market Data 
Markets 
AI
